Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 29, 2025. Further, the company has submitted the Exchange a copy of Srutinizers report.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova held its 47th AGM on August 29, 2025 via video conferencing, attended by 85 members representing about 7.03 crore equity shares. All five resolutions were passed with overwhelming majority, including adoption of FY25 audited financial statements, declaration of a dividend of Rs. 5 per share, re-appointment of Chairman Shyam S. Bhartia and Managing Director Priyavrat Bhartia (both via retirement by rotation), and appointment of Sanjay Grover & Associates as Secretarial Auditor for five years. The Chairman highlighted strong FY25 results: consolidated revenue grew 8% to Rs. 72 billion, EBITDA rose 24% to Rs. 12.3 billion with margins expanding 220 bps to 16.9%, and normalised PAT jumped 112% to Rs. 4.15 billion. Net Debt/EBITDA improved from 2.5x to 1.1x. The company reiterated its Vision 2030 of doubling revenue, achieving 23-25% EBITDA margins, and reaching zero net debt. Q1 FY26 revenue grew 10% to Rs. 19 billion. Management also flagged a planned transfer of the API business to wholly-owned subsidiary Jubilant Biosys and a US$50 million investment to add 6 new PET radiopharmacies.
Routine procedural filing — all resolutions passed with near-unanimous support, signalling strong shareholder approval for management. The dividend declaration of Rs. 5 per share is positive for income-seeking investors. The strong FY25 earnings growth, Vision 2030 targets, and zero US tariff exposure are constructive signals for the stock, though no fresh material announcement beyond AGM routine disclosures.